多索茶碱片联合布地奈德治疗支气管哮喘的临床研究

目的探讨多索茶碱片联合吸入用布地奈德混悬液治疗支气管哮喘的临床疗效。方法选取2014年1月—2015年7月延安市人民医院收治的支气管哮喘患者96例,按随机数字表法分为对照组和治疗组,每组各48例。对照组给予吸入用布地奈德混悬液200μg,1次/d。治疗组在对照组的基础上口服多索茶碱片0.2 g,2次/d。两组均连续治疗3个月。观察两组临床疗效,比较两组患者临床症状消失时间、嗜酸粒细胞比例、呼出气一氧化氮(FeNO)、细胞因子水平、肺功能和ACT评分。结果治疗后,对照组、治疗组的总有效率分别为77.1%、91.7%。两组总有效率比较差异具有统计学意义(P0.05)。治疗后,治疗组哮鸣音消失时间、气喘消失时间、咳嗽消失时间均明显短于对照组,两组间比较差异具有统计学意义(P0.05)。治疗1、3个月后,两组患者嗜酸粒细胞比例、FeNO均显著降低,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组这些观察指标的降低幅度明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗1、3个月后,两组患者IL-4水平显著降低,IFN-γ水平明显升高,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组这些观察指标的改善幅度明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗1、3个月后,两组FVC、FEV1、FEV1%、PEF明显升高,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组这些观察指标的升高幅度均明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗1、3个月后,两组ACT评分明显升高,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组这些观察指标的升高幅度均明显优于对照组,两组比较差异具有统计学意义(P0.05)。结论多索茶碱片联合吸入用布地奈德混悬液可有效治疗支气管哮喘,降低患者嗜酸性粒细胞比例、FeNO、细胞因子,改善哮喘症状和肺功能,升高ACT评分,值得临床推广和应用。

Clinical study on Doxofylline Tablets combined with budesonide in treatment of bronchial asthma

Objective To discuss the clinical effect of Doxofylline Tablets combined with Budesonide Suspension for inhalation in treatment of bronchial asthma. Methods Patients (96 cases) with bronchial asthma in Yan’an People’s Hospital from January 2014 to July 2015 were randomly divided into the control and treatment group, and each group had 48 cases. The patients in the control group were given udesonide Suspension for inhalation 200 μg, once daily. The patients in the treatment group were po administered with Doxofylline Tablets on the basis of the control group 0.2 g, twice daily. The patients in two groups were treated for 3 months. After treatment, the efficacy was evaluated, and disappearance times of clinical symptoms, eosinophils count, FeNO, cytokines, pulmonary function, and ACT score in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 77.1% and 91.7%, respectively, and there were differences between two groups (P < 0.05). After treatment, the wheeze disappeared time, wheezing disappearance time, and cough disappeared time in treatment group were shorter than those in control group, with significant difference between two groups (P<0.05). After treatment for 1 and 3 months, eosinophils count FeNO, and IL-4 level in two groups were significantly decreased, but IFN-γlevel, FVC, FEV1, FEV1%, PEF, and ACT score were significantly increased, and the differences were statistically significant in the same group (P<0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Doxofylline Tablets combined with Budesonide Suspension for inhalation has clinical curative effect in treatment of bronchial asthma, and can decrease eosinophils count, FeNO, and cytokines, improve asthma symptoms and pulmonary function, increase ACT scores, , which has a certain clinical application value.